靶向CD47-SIRPα信号轴：B细胞淋巴瘤免疫治疗的当前研究
Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
作者信息
Zhang Jin, Jin Shenhe, Guo Xiaojun, Qian Wenbin
机构信息
1 Department of Hematology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, P.R. China.
2 Department of Hematology, First Affiliated Hospital of Jiaxing University, Jiaxing, P.R. China.
出版信息
J Int Med Res. 2018 Nov;46(11):4418-4426. doi: 10.1177/0300060518799612. Epub 2018 Sep 18.
The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIRPα. Multiple studies have detected high CD47 expression on the surface of tumor cells, which indicates poor prognosis. Treatments that block the interaction of CD47 and SIRPα significantly suppress tumor growth and metastasis through diverse mechanisms, such as phagocytosis, antibody-dependent cellular cytotoxicity, and apoptosis. Recently, several studies have reported increased CD47 expression on different types of lymphoma cells, indicating that the CD47-SIRPα pathway can be used as a therapeutic target in lymphoma. This review focuses on the role of CD47-SIRPα in B-cell lymphoma and discusses promising therapeutic strategies targeting the CD47-SIRPα axis, which yield insights into the immunotherapy of B-cell lymphoma.
免疫系统在癌症发生和发展中的作用已得到广泛研究。值得注意的是，免疫疗法已成为一种有前景的癌症治疗方法。CD47是免疫球蛋白超家族的成员，通过与信号调节蛋白α（SIRPα）结合，在癌症的免疫调节中发挥重要作用。多项研究检测到肿瘤细胞表面CD47表达较高，这表明预后较差。阻断CD47与SIRPα相互作用的治疗方法可通过多种机制，如吞噬作用、抗体依赖性细胞毒性和凋亡，显著抑制肿瘤生长和转移。最近，多项研究报道不同类型淋巴瘤细胞上CD47表达增加，这表明CD47-SIRPα通路可作为淋巴瘤的治疗靶点。本综述重点关注CD47-SIRPα在B细胞淋巴瘤中的作用，并讨论针对CD47-SIRPα轴的有前景的治疗策略，从而为B细胞淋巴瘤的免疫治疗提供见解。
Zotero 插件